SAN FRANCISCO—Men recently diagnosed with prostate cancer are at elevated risk of cardiovascular death and suicide, according to separate analyses of a cohort of Swedish men.

MILAN—Intravesical alkalized lidocaine (PSD597) may be an effective short-term and possibly long-term treatment for patients with interstitial cystitis/painful bladder syndrome (IC/PBS), data suggest.

IN 2007, an international panel convened by the American Urological Association (AUA) and the European Association of Urology (EAU) updated the AUA ureteral stone guidelines. Most notably, the new guidelines reflect a pragmatic addition to the urologist's armamentarium: medical expulsive therapy (MET). MET is defined as the use of pharmaceutical agents to improve urinary stone passage rates and the time to stone passage in select individuals.

WASHINGTON, D.C.—Percutaneous declotting of hemodialysis grafts less than 30 days from initial placement may result in shorter secondary patency compared with declotting of older grafts, according to researchers.

SAN FRANCISCO—Ferumoxytol, a novel IV iron replacement drug, may be more effective than oral iron in hemodialysis patients receiving anemia treatment with an erythropoiesis-stimulating agent (ESA), according to study findings presented here at Renal Week 2007.

PRELIMINARY DATA suggest that severe acne, as measured by tetracycline use for four or more years, may be associated with an increased risk of prostate cancer, according to a recent report.

SAN ANTONIO—Kidney and other solid organ recipients are largely unaware of their elevated risk for skin cancer, according to data presented here at the American Academy of Dermatology annual meeting.

BEVACIZUMAB USED in combination with interferon alfa as a first-line treatment for metastatic renal cell carcinoma (RCC) nearly doubled progression-free survival in patients taking part in an international phase III trial.

SAN FRANCISCO—Microalbuminuria (MA) predicts the development of overt proteinuria at two years in patients with HIV infection, data suggest.

BOSTON—Among the various racial and ethnic groups in the United States, Hispanics have the worst response to treatment for proliferative nephritis due to systemic lupus erythematosus (SLE), data show.